z-logo
open-access-imgOpen Access
Isolation and phenotypic characterization of Gallibacterium anatis biovar haemolytica from a hen with hemorrhagic ooforitis
Author(s) -
I. Sorescu,
Luminiţa Maria Romaşcu,
M Ionescu,
A. Popovici,
C. Stoica,
Florica Bărbuceanu
Publication year - 2021
Publication title -
romanian biotechnological letters
Language(s) - English
Resource type - Journals
eISSN - 2248-3942
pISSN - 1224-5984
DOI - 10.25083/rbl/26.6/3090-3094
Subject(s) - biovar , microbiology and biotechnology , biology , enrofloxacin , ciprofloxacin , nalidixic acid , ampicillin , gentamicin , isolation (microbiology) , antibiotics , bacteria , genetics
Objective: the isolation and phenotypically identification of a Gallibacterium anatis biovar haemolytica strain from a hen with hemorrhagic ooforitis; the antimicrobial susceptibility testing of this isolate. Methods and results: a strain of G. anatis biovar haemolytica, was isolated and phenotypic identified by morphological, cultural and biochemical characters examination, with API 20 E, API 20 NE, API STAPH, API ZYM tests and ABIS online software. The antimicrobial susceptibility of the isolate was performed using the standard disk diffusion method. Conclusions: a strain of G. anatis biovar haemolytica was isolated and phenotypically identified from a hen. From our knowledge, this is the first reporting in Romania of isolation and identification of G. anatis biovar haemolytica. The Gah IDSA 161 strain could be phenotypic identified only by ABIS on line software, Pasteurellaceae Database version, unifying the results of four API kits and other biochemical tests. The isolate showed a multi-drug resistant profile to tetracyclines (tetracycline, oxitetracycline, doxicyclin), floroquinolones (enrofloxacin, ciprofloxacin), ampicillin, trimethoprim, nalidixic acid, clindamycin, and it was susceptible to sulfonamide, sulfomethoxazole/trimethoprim, gentamicin, cephalothin, streptomycin, amoxicilin/clavulanic acid.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here